Saturday 17 October 2026
Export INMD’s income statement to Excel — free account
InMode Ltd.
INMD Healthcare Medical Devices
InMode Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $370.5 million, down 6.16% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 31.0% and free cash flow fell 12.6%, each against the same quarter a year earlier.
14.16
0.16
−1.12%
Follow INMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
11.70 | 9.91 | 10.06 | 6.83 |
+8 more quarters Free account |
P/S ratio |
2.30 | 2.32 | 2.56 | 2.59 | |
P/FCF ratio |
10.43 | 10.14 | 11.26 | 9.99 | |
P/Operating CF |
40.91 | 56.37 | 41.87 | 38.54 | |
P/B ratio |
1.26 | 1.27 | 1.39 | 1.34 | |
Price to Tangible BV |
1.26 | 1.27 | 1.39 | 1.34 | |
EV/Sales |
0.96 | 0.88 | 1.06 | 1.13 | |
EV/EBITDA |
5.15 | 4.10 | 4.58 | 4.67 | |
EV/Operating CF |
4.31 | 3.81 | 4.62 | 4.32 | |
EV/FCF |
4.36 | 3.86 | 4.68 | 4.35 | |
Quick Ratio |
7.28 | 7.88 | 8.83 | 8.71 | |
Current Ratio |
8.18 | 8.80 | 9.88 | 9.75 | |
Net Debt/EBITDA |
(40.30) | (52.50) | (21.22) | (25.28) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.52 | 0.51 | 0.48 | 0.48 | |
Operating CF/Net income |
1.23 | 1.33 | 0.84 | 1.12 | |
Capex/Depreciation |
(1.18) | (0.98) | (3.07) | (0.86) | |
Research and Development Expense of Revenue |
3.82% | 4.32% | 3.38% | 3.80% | |
Selling, General and Administrative Expense of Revenue |
58.17% | 58.47% | 49.88% | 51.38% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3.88% | 3.29% | 2.41% | 2.89% | |
Graham Net Nets |
0.65 | 0.68 | 0.65 | 0.62 | |
Graham Number |
0.00 | 0.00 | 18.63 | 0.00 | |
Earnings Yield |
8.55% | 10.09% | 9.94% | 14.63% | |
Free Cash Flow Yield |
9.58% | 9.86% | 8.88% | 10.01% | |
Revenue per Share |
1.62 | 1.29 | 1.61 | 1.47 | |
Operating CF per Share |
0.36 | 0.24 | 0.35 | 0.39 | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
0.35 | 0.24 | 0.34 | 0.38 | |
Cash per Share |
8.51 | 8.47 | 8.59 | 8.41 | |
Shareholders Equity per Share |
10.68 | 10.43 | 10.57 | 10.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.68 | 10.43 | 10.57 | 10.32 | |
Free Cash Flow |
20.84 | 15.21 | 22.14 | 24.33 | |
Working Capital |
570.56 | 603.43 | 627.88 | 597.96 | |
Capital Expenditures |
(0.21) | (0.17) | (0.53) | (0.13) | |
Net Current Asset Value |
558.80 | 591.20 | 615.39 | 585.07 | |
EV/EBIT |
5.20 | 4.14 | 4.62 | 4.71 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
12.44 | 10.87 | 11.12 | 10.81 | |
| Other line items | |||||
Average Receivables |
68.60 | 65.07 | 63.83 | 60.51 | |
Average Payables |
18.14 | 15.95 | 15.85 | 15.25 | |
Average Inventory |
69.89 | 67.59 | 66.80 | 65.48 | |
Average Assets |
714.34 | 727.79 | 776.05 | 760.14 | |
Average Common Equity |
— | — | 674.68 | — |
Columns are period end dates